Cautiously positive: a 55% chance Foresight Health reaches its ~$38M base path or better by 2030 — but every number here is an analyst scenario
Asked:
“Will this company do well? Foresight Health—predict future valuation and revenue and how easy it is to prospect and get customers.” The company is the San Francisco AI-native startup founded in 2025 selling fully managed Medicare CCM/PCM programs to specialty clinics, with a stated $8.5M seed round.
This report models 4 scenarios × 5 years (2026–2030, 20 rows, nominal USD millions) for Foresight Health. There is no verified public revenue or disclosed valuation: everything below is an analyst scenario built from company-associated claims and Medicare CCM/PCM economics, with revenue = clinics × enrolled patients per clinic × assumed vendor revenue per patient per month × 12 (vendor PMPM of $28–$52, not gross Medicare reimbursement).
Modeled annual revenue by scenario, 2026–2030
Base (40%)
Upside (15%)
Downside (25%)
Shutdown (20%)
Colour = scenario; line ends carry 2030 revenue and illustrative terminal valuation. Hover a line or point for detail.
Probability-weighted 2030 outcome: $35.0M revenue and $268.3M valuation — the weighted valuation sits above the $225M base case only because the 15% billion-dollar upside skews the distribution; it is not the most likely outcome. Basis: company profile at
pitchbook.comThe strongest verified-adjacent signals are company-associated, not audited: an $8.5M seed from Quiet Capital, Susa Ventures and Neo, and a claim of Emi-powered care deployed to over 5,000 Medicare patients “at full capacity” —
linkedin.comClaimed 3–5× month-over-month growth since launching care delivery in early 2025 supports the base and upside curves but is a company/associated-source claim —
paraform.comAn illustrative current post-money of $34.0M–$56.7M assumes mechanically that the $8.5M seed bought 25%–15%; it is not a reported valuation — service scope per
foresighthealth.ai
2030 valuation distribution
Bar length = illustrative 2030 valuation; label carries the scenario probability. Weighted mean $268.3M shown as a marker.
Prospecting to launch scorecard
Building a target list — ease 8/10 (easy: specialties, Medicare mix and eligible diagnoses are identifiable)
Securing a first serious meeting — difficulty 6/10 (moderate)
Closing and launching — difficulty 8/10 (hard; estimated 3–9 month sales cycle)
The buyer must trust Foresight with patients, compliance, billing documentation, clinical staffing and workflow integration. Best initial segments: specialties with concentrated Medicare populations, frequent chronic-condition follow-up, measurable avoided workload, and one accountable physician-owner or administrator. The strongest pitch is a practice-specific pro forma plus a low-risk pilot — not generic AI messaging.
Key assumptions and risks
- Assumptions: vendor PMPM revenue of $28–$52 (the model does not assume Foresight keeps the entire billed Medicare amount); base path grows from 10 clinics × 180 patients in 2026 to 225 clinics × 325 patients in 2030; scenario weights 40% base, 25% downside, 20% shutdown, 15% upside.
- Reported facts: $8.5M seed disclosed; fully managed CCM/PCM service scope described on the company site.
- Company-associated claims (unaudited): 3–5× month-over-month growth; 5,000+ Medicare patients served at full capacity.
- Risks: labor-heavy service delivery, patient consent and engagement, Medicare billing and audit exposure, specialty-clinic concentration, EHR/workflow integration, and strong incumbents.
What would change the forecast
- Verified count of active enrolled patients
- Realized vendor PMPM revenue versus the assumed $28–$52
- Gross margin on the managed-care service
- Verified clinic count and enrollment conversion rate
- Patient and clinic churn
- Actual sales-cycle length versus the estimated 3–9 months
- Clean Medicare billing and audit history
Full scenario model
| Scenario | Prob. | Year | Clinics | Patients/clinic | PMPM $ | Revenue $M | 2030 valuation $M | Source |
|---|
Analyst scenario model, 20 rows (4 scenarios × years 2026–2030), researched 2026-09-11, nominal USD. Revenue = clinics × avg enrolled patients per clinic × assumed vendor PMPM × 12; valuations are illustrative multiples, not reported. Probability-weighted 2030: $35.0M revenue, $268.3M valuation. Source URLs span multiple independent hosts; no single URL backs more than 15% of rows. Basis-fact text is truncated in the table for space.